We showed previously that exogenous overexpression of C3G, a guanine nucleotide releasing factor (GEF) for Rap1 and R-Ras proteins, blocks the focus-forming activity of cotransfected, activated, sis, ras and v-raf oncogenes in NIH 3T3 cells. In this report, we show that C3G also interferes with dbl and R-Ras focus-forming activity and demonstrate that the transformation suppressor ability of C3G maps to its Crk-binding region (SH3-b domain). Using full-length C3G and C3GDCat mutant, lacking catalytic domain, we showed here that overexpression of cotransfected C3G or C3GDCat inhibited oncogenic Hras lys12 -mediated phosphorylation of ERK, without altering Ras and Raf-1 kinase activation. We also showed that, overexpressed C3G and C3GDCat inhibited the viability of oncogenic Ras-induced colonies in soft agar, indicating that C3G interferes with the anchorageindependent growth of Ras-transformed cells in a Rap1-independent manner. Consistent with both observations, overexpression of exogenous C3G and C3GDCat also caused downregulation of Ras-induced cyclin A expression. Altogether, our results indicate that C3G interferes with at least two separate aspects of oncogenic transformation -cell cycle progression and loss of contact inhibition -and that these inhibitory effects probably account for its transformation suppressor activity.
Introduction
The C3G gene product is a modular protein acting as an exchange factor for the Rap and R-Ras proteins in fibroblasts (Gotoh et al. , 1995 (Gotoh et al. , , 1997 Ohba et al., 2000) . C3G binds to the N-terminal SH3 domain of the adaptor protein Crk through four proline-rich stretches encompassing the central region of the molecule (residues 282-616 of the human protein) (Knudsen et al., 1994; Tanaka et al., 1994) . The C3G molecule also encompasses CDC25-H and REM domains characteristic of the guanine nucleotide exchange factors (GEFs) for the Ras family of proteins (Quilliam et al., 2002) .
C3G is activated by multiple signals depending on the cell type (McLeod et al., 1998; Reedquist and Bos, 1998; Sakkab et al., 2000; Yokote et al., 1998; York et al., 1998; Zhu et al., 1998) , and can also act as a mediator in the activation of several pathways, including the JNK, ERK and Rac signaling pathways (York et al., 1998; Ishimaru et al., 1999; Mochizuki et al., 2000; Abassi and Vuori, 2002) .
C3G signaling also plays a crucial role in integrinmediated cell adhesion and migration (de Jong et al., 1998; Arai et al., 1999 Arai et al., , 2001 Uemura and Griffin, 1999) , assembly and stabilisation of focal adhesion (Li et al., 2002; Voss et al., 2003) and vascular myogenesis (Voss et al., 2003) , a function that probably involves activation of Rap1 or R-Ras (de Jong et al., 1998; Arai et al., 1999 Arai et al., , 2001 Uemura and Griffin, 1999) . In fact, disruption of C3G expression in mice affects adhesion and spreading of embryonic fibroblasts (Ohba et al., 2001) . Cell adhesion plays an essential role in regulating proliferation during the G1 phase of the cell cycle, and loss of substrate adhesion is a requirement for oncogenic transformation (Guadagno et al., 1993) . Oncogenic Ras induces anchorage-independent growth in rodent fibroblast cell lines measured as the ability to form colonies in a semisolid medium. It has been described that Ras drives cyclin A expression, a most critical step for induction of anchorage-independent growth by this oncogene (Yang et al., 1998) .
We have demonstrated previously that exogenously overexpressed C3G suppresses Ras-mediated transformation, an effect that appears to be independent of its CDC25-H, catalytic domain (Guerrero et al., 1998) . The aim of this study was to map the specific region of C3G required for its transformation suppression activity and to determine the mechanisms by which C3G exerts such an effect. Here we show that the Crk-binding domain is responsible for the transformation suppression ability of C3G, and that this is not exclusive of Ras-mediated pathways but seems to be a more general mechanism affecting other oncogenes like dbl or R-ras. Our data suggest that the mechanism of suppression involves inhibition of Ras-dependent ERK activation, and cyclin A expression. Furthermore, such an inhibitory effect is accompanied by a decrease in the viability of cells under nonadherent conditions. Therefore, at least two aspects of oncogenic transformation, cell cycle regulation and anchorage-independent growth, are altered by overexpression of C3G. These alterations may account, at least in part, for the inhibitory effect of C3G on oncogene-mediated transformation of NIH 3T3 fibroblasts.
Results

Transformation suppressor activity of C3G maps to its SH3-binding domain
We have previously shown that the transformation suppressor activity of C3G on sis, ras and raf oncogenes was independent of its catalytic domain (Guerrero et al., 1998) . To further characterize the C3G region responsible for the suppression effect, we constructed additional deletion mutants, including DNC3G (lacking the first 636 nucleotides of the gene) and C3GSH3-b (containing only the Crk-binding region; n625-n1982), which were cloned into mammalian expression vector pLTR2 (DiFiore et al., 1987) (Figure 1a ). These constructs were transfected into NIH 3T3 cells alone or in combination with a Neo-selectable construct expressing oncogenic H-ras (pMEXneo Hras lys12 Benito et al., 1991) . Transfectants were selected with G418 and/ or HAT/gpt according to plasmid combinations. Protein extracts from NIH3T3 cells cotransfected with Ras and these new C3G constructs and selected for double resistance (neo þ gpt) showed a high level of expression of both C3G clones and Hras lys12 peptides (Figure 1b ). We observed in several independent experiments that both the DNC3G and the C3GSH3-b constructs were able to decrease about 40-75% the number of Rasinduced foci (Figure 1c, d) , a reduction similar to that observed with pLTR2C3G and pLTR2C3GDCat constructs ( Figure 1c ) (Guerrero et al., 1998) . These results confirmed that the SH3-b region is necessary for C3G to exert its transformation suppressor activity.
C3G suppresses the transforming ability of dbl and R-ras oncogenes
To determine whether the transformation suppressor effect of C3G is limited to components of Rasdependent pathways or it involves more general mechanisms, we studied the effect of our C3G mutant constructs on dbl and R-ras cotransfected oncogenes. Figure 2a , b shows that C3G was also able to inhibit foci formation by these two oncogenes and that, as for ras, (Guerrero et al., 1998) , constructs in which the catalytic domain had been eliminated (C3GDCat) showed an even higher inhibitory effect than the complete C3G over R-ras and dblinduced transformation (Figure 2a, b) . Expression of both proteins was monitored by Western blotting (data not shown). These results indicate that the suppressor activity of C3G is not restricted to Ras pathways, but it seems to involve a more general mechanism.
C3G does not affect ras, raf-1 and MEK-1 activation
Results from our previous work (Guerrero et al., 1998) indicated that C3G blocked malignant transformation triggered by components of the Ras-Raf pathway. Thus, a first question is whether C3G directly affects Ras and/or Raf-1 activities. We performed Ras activity assays on cells permanently transfected with C3G, alone or in combination with oncogenic ras. Figure 3a shows that the presence of C3G did not affect the amount of Ras-GTP complex present in cells treated with FBS for various periods of time. Furthermore, regarding Raf-1, we also showed in transient tranfections that C3G did not affect the mobility shift due to Raf-1 phosphorylation ( Figure 3b ). Since Raf-1 can be phosphorylated either for activation or for inhibition (Marais et al., 1995; Sozeri et al., 1992; Dhillon et al., 2002) to ensure that C3G is not affecting Raf-1 activity we studied, in permanently transfected clones, the phosphorylation status of MEK1, a known Raf-1 substrate, using an anti-phosphoMEK1 antibody that specifically recognizes the serine residues (ser217 and ser221) phosphorylated by Raf-1. Figure 3c shows that C3G did not affect Raf-1-dependent MEK1 phosphorylation, suggesting that, as with Ras, Raf-1 activity is not altered by C3G.
C3G expression inhibits ras-induced ERK phosphorylation
To gain further insight into the mechanism of suppression, and given that both Ras and Raf are components of the ERK/MAPK pathway, we studied whether C3G affects Ras-mediated ERK activation, measured as p44/ 42 ERK phosphorylation. Permanently transfected clones expressing C3G and Hras lys12 , alone or in combination, were starved for 20 h and stimulated for 5 min with 10% fetal bovine serum (FBS) or 25 ng/ml platelet-derived growth factor (PDGF) before determination of the levels of phosphorylated ERK. Figure 4a shows that oncogenic H-Ras-mediated phosphorylation of ERK is inhibited in clones expressing C3G. We confirmed this result in transiently transfected cells with the same DNAs. Figure 4b show that the levels of Ras-mediated ERK phosphorylation decrease both in starved and exponentially growing cells that transiently overexpress C3G. This inhibitory effect was not Rap1-or R-Ras-mediated since C3GDCat mutant, lacking the catalytic domain, also exhibited the same effect on ERK activation (Figure 4c ).
C3G alters anchorage-dependent properties of fibroblast cells
We have previously shown that C3G does not affect NIH 3T3 cells viability in adherent conditions, and that C3G-expressing cells exhibit a growth rate similar to cells transfected with vector alone (Guerrero et al., 1998) . Besides faster growth, another indicator of tumorigenicity is the ability of transformed cells to form colonies in semisolid medium. Thus, we studied whether C3G may affect anchorage-independent growth of oncogenic Ras-expressing cells. NIH 3T3 clones expressing C3G, C3GDCat or Hras lys12 alone or in combination were seeded in soft agar as described in Materials and methods, and the number and size of resulting, growing colonies was determined. Figure 5 shows that the expression of C3G and C3GDCat reduced dramatically the growth (measured as the size of the colonies and the number of colonies larger than B3000 mm 3 ) of Ras-induced proliferating colonies in soft agar, which is in concordance with its suppression role. This result clearly indicate that C3G exerts a strong inhibitory effect over the ability of Ras-transformed cells to grow in soft agar independently of its exchange activity.
The above results suggest that C3G-expressing cells may display a higher substrate dependence, and that C3G may confer augmented adhesive properties to the cells. To study this hypothesis, and based on recent reports showing that C3G plays an essential role for adhesion to laminin and gelatin (Voss et al., 2003) we studied the adhesiveness of C3G and C3GDCat expressing cells using laminin-1-coated wells. Figure 6 shows that ectopic expression of C3G increases B40-60% the adhesion to laminin-1 of wild-type NIH 3T3 cells or cells cotransfected with Hras lys12 . However, expression of C3GDCat mutant did not increase the adhesion to laminin. These results indicate that the higher adhesiveness conferred by overexpression of C3G is Rap1-dependent and does not account for the transformaction suppression effect on oncogenic transformation.
Effects of C3G on cell cyclin A expression
Mitogenic signals promote G1 phase entry and cell cycle progression (Peeper et al., 1997) , which is regulated by cyclin-CDKs complexes (Takuwa and Takuwa, 2001 ). The levels of most CDKs are relatively constant during the cell cycle (Yam et al., 2002) ; thus, the regulation of CDKs activities must be dependent on the corresponding cyclins. Since cyclin A is essential for anchorage-independent growth and its expression is regulated by Ras (Kang and Krauss, 1996; Yang et al., Takuwa and Takuwa, 2001) , we studied whether C3G affects cyclin A expression. NIH 3T3 clones expressing C3G and/or Hras lys12 were grown exponentially and the levels of cyclin A determined by immunoblotting. Figure 7 shows that Ras-induced cyclin A expression was clearly inhibited by both C3G and C3GDCat overexpression, which is consistent with the inhibitory effect of C3G or C3GDCat on Hras lys12 -mediated growth in suspension. Other cell cycle components studied like cyclin D and cyclin E were not altered by C3G (data not show).
Discussion
Previously, we have shown that overexpression of transfected C3G suppresses oncogenic transformation mediated by cotransfected Ras oncogenes in NIH 3T3 fibroblasts. We also observed that such suppression was independent of the presence of the CDC25-H, catalytic, domain in the transfected C3G constructs (Guerrero et al., 1998) . In the present work, we have demonstrated that the C3G region responsible for this effect maps to its amino-terminal, SH3-binding domain. Such an observation suggests that Rap1 (a small GTPase activatable by C3G), in spite of its previous depiction as a Ras antagonist (Sakoda et al., 1992) , may not be the intermediary of the process of C3G-dependent suppression of transformation.
We have also shown here that C3G inhibits focus formation induced not only by ras but also by the dbl and R-ras oncogenes. This observation suggests that the suppressor function of C3G may involve more general mechanisms, not limited only to Ras oncogenes or pathways. The inhibitory effect on R-Ras-mediated transformation is somewhat paradoxical, as R-Ras has also been described to be activated by C3G, although the GEF that exhibits highest exchange activity on RRas is Grf1 (Gotoh et al., 1997) . It has to be mentioned that these published results refer to work using COS7 cells, and thus the differences in cell type may account for some of these discrepancies.
To gain an insight into the suppression mechanism, and considering that malignant transformation by Ras is the result of the cooperation between various downstream pathways (Rodriguez-Viciana et al., 1997; Hamad et al., 2002) , we studied the effect of C3G on some of the Ras effectors. Our results showed that whereas C3G does not affect activation of either Ras, Raf-1 or MEK1, it clearly inhibits Ras-induced ERK1/2 phosphorylation. The effect of C3G on Ras-mediated ERK activation was not due to the particular characteristics of the permanently transfected clones, as (i) the clones used were, in fact, mass cultures of the corresponding permanent transfections and (ii) we were able to confirm the results in transiently transfected cell cultures. Obviously, the observed effect was much lower under these conditions due to the limited transfection efficiency of NIH 3T3 cells (around 10%). In this case, we could only observe the inhibitory effect of C3G on ERK activation in nonstimulated cells (both starved and serum-growing nonsynchronic cultures), but not in growth factor-stimulated cells, probably due to the masking effect of the PDGF-or serum-dependent ERK activation on the 90% nontransfected cells. C3GDCat mutant, lacking the catalytic domain, also inhibited Ras-mediated ERK activation, which is in agreement with its transformation suppression effect (Guerrero et al., 1998) and confirms that ERK participates in the suppression mechanism. It should be mentioned here that C3G is only affecting the serum-mediated shortterm activation of ERK, since we have previously shown that sustained ERK activity is not altered (Guerrero et al., 1998) .
We have also observed that C3G, but not C3GDCat, exerts an inhibitory effect on the PI3K-Akt pathway, which suggests that this pathway seems not to be involve in the transformation suppression mechanism (data not shown).
Ras induces anchorage-independent growth via multiple pathways by downregulating multiple adhesionregulated cell cycle events, such as cyclin A expression (Guadagno et al., 1993; Kang and Krauss, 1996 ; Yang , 1998) . Cyclin A is required for initiation and progression through the S phase (Takuwa and Takuwa, 2001) , and its expression is dependent on cell adhesion (Guadagno et al., 1993) . In fact, only cells overexpressing cyclin A are able to cycle in suspension (Guadagno et al., 1993; Kang and Krauss, 1996; Schulze et al., 1996) . This is in concordance with our results where cells expressing C3G and C3GDCat showed lower levels of cyclin A and reduced ability to grow in suspension (Figures 5-7) . Thus, according to our results, C3G antagonizes cyclin A expression (probably through inhibition of ERK) an adhesion-regulated cell cycle event. Increased cyclin A expression has been detected in many tumors (Yam et al., 2002) ; thus, our results showing reduced expression of cyclin A in C3G and C3GDCat expressing cells support the notion of C3G as a transformation suppressor gene by a mechanism that does not involve Rap1 activation.
Our results are in agreement with previous work showing that the activation of ERK, and some cell cycle events like cyclin A expression, are the key components involved in the ability of cells to grow in nonadherent conditions (Renshaw et al., 1997; Howe et al., 1998) . These authors showed that the activation of ERK by MEK1, but not the assembly of focal adhesions or the phosphorylation of focal adhesion proteins, is the critical step that is altered in cells growing in suspension. This is in concordance with our results where not only C3G, which may activate focal adhesion proteins via Rap1, but also C3GDCat inhibits growth in soft agar.
In conclusion, the results presented here indicate that C3G inhibits Ras-mediated oncogenic transformation, regardless of its guanine nucleotide exchange activity, by interfering with the activation of the ERK pathway, which then results in inhibition of cyclin A expression and anchorage-independent growth. In addition, our results also show an effect of C3G on other oncogenes, like dbl and R-ras, suggesting that the inhibitory effect of C3G on malignant transformation may involve more general mechanisms, probably affecting components of the cell adhesion machinery. Further studies are necessary to clarify the function and the mechanisms by which C3G exerts its inhibitory effect on oncogenemediated transformation. The fact that C3G inhibits ERK activity without affecting other components of the Ras-ERK pathway suggests the existence of putative effector molecule(s) able to interact with the Crk binding domain of C3G and thus inhibiting ERK activation by still unknown mechanism(s). An interesting possibility, consistent with the results reported here, would be the activation of a potential phosphatase(s) acting downstream of C3G, which might be responsible for the observed inhibition of ERK phosphorylation. Further studies will be necessary to identify such a hypothetical phosphatase, or any other potential effector(s) 
Materials and methods
Construction of expression vectors for the DNC3G and C3GSH3-b fragments
Construct DNC3G was made by deletion of the first 212 amino acids of C3G. A PshAI-BamHI fragment containing nucleotides from n637 to n3248 (considering n1 the A in the first ATG codon) was subcloned into pSP72/EcoRV-BamHI, and subcloned again as a BglII-BamHI fragment into pCEVKZ-HA (Miki et al., 1989) . From the new construct, the DNC3G fragment was transferred by XhoI-BglII digestion into pLTR2 XhoI-BamHI (DiFiore et al., 1987) . C3GSH3-b domain was cloned into pLTR2 by PCR amplification of a fragment enclosing from amino acid 209 to 660, comprising all the polyproline sequences important for SH3-binding, using oligos AF33 (GCTCCTCGAGATGAAG-CAGGGACGTCCGTC) and AF34 (CTTCGGATCCC-GACTGAGCCGACTCC), containing, respectively, a XhoI and a BamHI site. After checking for the absence of mutations by sequencing, the resulting fragment was cloned into pLTR2 by XhoI-BamHI digestion.
Permanent transfections and quantitation of focus-forming activity NIH3T3 cells were transfected by the calcium phosphate method (Chen and Okayama, 1987) and individual colonies were isolated as described previously (Guerrero et al.,. 1998) .
Focus forming activity was quantified after the transfection experiments by growing transfected NIH3T3 cells in the absence of selection for 2 weeks. The plates were then stained with a Giemsa solution and the number of morphologically transformed foci was counted.
Transient transfections
NIH 3T3 cells were transiently transfected using the FuGENE 6 Transfection Reagent (Roche Molecular Biochemicals). FuGene 6 was diluted in 300 ml serum-free medium and DNA added at a ratio 3 : 1 (18 ml FuGENE : 6 mg DNA). After 15 min of incubation, the mixture was added dropwise to 60-70% confluent cells in 100 mm plates. After 24 h of incubation at 371C and 5% CO 2 , cells were serum-deprived for an additional 24 h and then treated with the corresponding agonists.
DNAs used in the transfection experiments included the constructs described above (DNC3G and C3GSH3-b fragments cloned in the pLTR2 vector for gpt selection), as well as clones described in a previous work (Guerrero et al., 1998) . Mammalian expression constructs of the different oncogenes were obtained from several sources: Hras lys12 in pMEXneo (Benito et al., 1991) , dbl in pZIPneoSV (Eva and Aaronson, 1985) and R-ras in pMEXneo (Sae´z et al., 1994) . Plasmids pLTR2 (DiFiore et al., 1987) and pMEXneo (Benito et al., In all experiments (both in transient and permanent transfectants), cells were stimulated with 20% FBS for 5 min or 25 ng/ml PDGF (platelet-derived growth factor) for 2 min. PD98059 (50 mM, 2 h before agonists) was used as negative controls of ERK activation.
Antibodies and immunological studies
In this study we have used the following antibodies: anti-C3G #1008 (Guerrero et al.,. 1998), anti C3G (C-19) and C3G (H-300), anti-H-Ras (C-20), anti R-Ras (C-20), anti-Dbl (3), antiRaf-1 (C-12), anti-ERK-1 (K-23) and anti-cyclin A (C-19) from Santa Cruz Biotechnologies (Santa Cruz, CA, USA); anti-Ras M90 (Lacal and Aaronson, 1986) ; anti-phospho-p44/ 42MAPK (thr202/tyr204) and anti-phosphoMEK-1/2 (Ser217/ 221) from Cell Signaling Technology, Inc. (Beverly, CA, USA); and anti-MEK1 from PharMingen (San Diego, CA, USA).
First antibodies were used at 1 mg/ml for #1008 antibody, 2 mg/ml for M90 antibody or 0.2 mg/ml for the rest. Anti-mouse or anti-rabbit horseradish peroxidase-conjugated antibodies (Amersham Biosciences, Uppsala, Sweden) were used as secondary antibodies. The authenticity of the signal was checked in parallel experiments in which the antibody was incubated for 30 min at room temperature with an excess of a specific blocking peptide (20-40 mg). Detection was performed using the ECL-Western blot detection system (Amersham Biosciences).
Ras activity assays
Cells were grown to confluence in 100-mm dishes and serum starved for 20-24 h followed by incubation with 10% FBS for the indicated times. After treatment, cells were washed twice with cold phosphate-buffered saline (PBS) and the levels of Ras-GTP were determined using an 'Ras activation assay kit' (Upstate Biotechnology, Lake Placid, NY, USA) as described previously (Guerrero et al., 2002) .
Raf-mobility shift assay
Activated Raf-1 was detected by mobility shift assay on NIH 3T3 cells transiently transfected with C3G and/or Hras lys12 , since phosphorylated Raf-1 shows a reduced electrophoretic mobility. An amount of 40 mg protein was loaded onto a 8% gel and the amount of Raf-1 was determined by immunoblotting with anti Raf-1 (C-12) from Santa Cruz Biotechnologies (Paasinen-Sohns and Holtta, 1997).
Soft agar assay
Serial cell dilutions at 10 6 , 10 5 and 10 4 cells/ml were mixed with 0.5%. Noble Agar in 1X DMEM þ 10% calf serum (CS) supplemented with G418, Killer HAT or both (100 ml of cell suspension in 4 ml of the above mixture) and added to 60 mm plates containing 4 ml 1% Agar þ 1 Â DMEM þ 10% CS. Plates were incubated at 371C in a humidified incubator and fed once a week for 14 days with 20 ml 1 Â DMEM þ 10% CS. Then, plates were stained with 1 ml of 0.005% crystal violet for more than 1 h and colonies counted using a dissecting microscope. The size of colonies was measured as volume applying the equation 4/3pr 3 , where r is the radius of foci.
Cell adhesion assay
Cell attachment was assayed in microtiter plates as described (Matter and Laurie, 1994) , http://iprotocol.mit. edu/protocol/ 292.htm. Briefly, cells were trypsinized, diluted to 2.0 Â 10 5 /ml in serum-free medium, added to the wells (previously coated overnight at 41C with 40 mg/ml laminin-1) and placed in an incubator for 30-60 min at 371C and 5% CO 2 . BSA (1%) was used as negative control. Cells were fixed by incubation with freshly diluted 1% glutaraldehyde in PBS for 10 min at room temperature and stained with 100 ml/well of freshly filtered 0.1% crystal violet for 25 min. After washing the cells, the dye was eluted with 0.5% Triton X-100 and the absorbance measured at 595 nm.
Statistical analysis
Data are represented as mean 7s.d. As comparisons were made between two experimental groups, an unpaired Student's t-test was used. Results were considered significant when po0.05.
